Close
Close

AstraZeneca - NF type1 With Inoperable Plexiform Neurofibromas

Partner

Not provided

Rare Disease

NF type1 With Inoperable Plexiform Neurofibromas

Sponsor

AstraZeneca

Access Program Information

This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options. All patients will continue to receive drug while they are deriving clinical benefit . Approximately 50 patients in the US will be treated as part of this protocol

Contact
Locations
  • United States
  • Washington, D.C., District of Columbia, United States

Free Newsletter